Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Infectious Diseases Epidemiology

Our team’s vision is to reduce the burden of infectious diseases in children and their families through comprehensive approaches to understanding the burden of disease, developing and optimising diagnosis and treatment strategies and evaluating and informing current and future prevention programs.

Our group has a particular interest in acute lower respiratory infections, commonly known as chest infections.

These conditions include bronchiolitis and pneumonia and occurs secondary to viral and bacterial infections including viral pathogens respiratory syncytial virus (RSV), influenza, human metapneumovirus and parainfluenza virus and bacterial pathogens including Streptococcus pneumoniae and Bordetella pertussis. Chest infections are a major cause of childhood morbidity with some population subgroups experiencing higher rates of severe disease including Aboriginal and/or Torres Strait Islander children, those with co-morbidities and those from a lower socio-economic background.

The work of the Infectious Disease Epidemiology team centres around three key themes:

  • Burden of Disease – understanding pathogen-specific burden of disease, temporal and seasonal trends in disease and perinatal risk factors to disease in population groups using a range of data sources.
  • Prevention and Policy – evaluating current prevention policy, such as vaccination policy at local and population levels, incorporating assessment of vaccine coverage, cost effectiveness and overall program performance in reducing the incidence of disease. We also use data to advocate for new immunisation programs, including RSV.
  • Diagnosis and Treatment - developing ways to improve surveillance of and the diagnosis and treatment of severe respiratory infections in children through prospective cohort studies, clinical trials and use of administrative health data.

Our team employs an array of methodologies including epidemiological analyses of large-scale population-based linked administrative health data; statistical and mathematical modelling; undertaking prospective cohort studies and clinical trials; and conducting social research.

Team leader

Associate Professor Hannah Moore
Associate Professor Hannah Moore

OAM BSc (Hons) GradDipClinEpi PhD

Head, Infectious Diseases Research

Professor  Christopher Blyth
Professor Christopher Blyth

MBBS (Hons) DCH FRACP FRCPA PhD

Centre Head, Wesfarmers Centre of Vaccines and Infectious Diseases; Co-Head, Infectious Diseases Epidemiology, Wesfarmers Centre of Vaccines and Infectious Diseases, Honorary and NHMRC Emerging Leadership Fellow

Team members (17)

Anita Williams
Anita Williams

MInfecDis MPhil(App Epi)

Research Officer, Infectious Diseases Epidemiology

Belaynew Taye
Belaynew Taye

MD, MPH, PhD

Research Officer, Infectious Disease Epidemiology

Carla Puca
Carla Puca

BSc, MPH, MIDI

Dr Minda Sarna
Dr Minda Sarna

M.App.Epid., PhD

Senior Research Officer

Huong Le
Huong Le

MA (Dev. Econ), MA (App. Stats), PhD (Econ)

Biostatistician & Data Analyst

Carolyn Finucane

Carolyn Finucane

Research Nurse

Cathy Pienaar

Cathy Pienaar

Honorary Team Member

Charlie Holland

Charlie Holland

PhD Student

Daniel Oakes

Daniel Oakes

PhD Student

Dhruv Shah

Dhruv Shah

Program Manager, Infectious Diseases Epidemiology Team

Fiona Giannini

Fiona Giannini

Mathematical Modeller

Joanne Harvey

Joanne Harvey

Clinical Trial Coordinator

Kate Britton

Kate Britton

PhD Student

Leslie-Ann Conway

Leslie-Ann Conway

Aboriginal Project Advisor

Meghan Paul

Meghan Paul

Project Coordinator

Muna Jibril

Muna Jibril

Student

Who is at risk of a respiratory syncytial virus hospitalisation? A linked, population-based birth cohort analysis in children aged less than 5 years

Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infections globally in children under five years. With the development of RSV prevention strategies, understanding risk factors and relation to age and population is useful for deciding the type of program implemented.

Respiratory Syncytial Virus Strain Evolution and Mutations in Western Australia in the Context of Nirsevimab Prophylaxis

Nirsevimab is a long-acting monoclonal antibody used to prevent respiratory syncytial virus (RSV) infection in infants and high-risk children. During the 2024 RSV season in Western Australia, 21 922 doses were administered to infants entering their first season and 1221 doses to at-risk children. In this context, the selection and spread of escape variants are a potential concern. This study aimed to investigate nirsevimab binding site mutations using clinical and wastewater data.

Collecting behavioural data across countries during pandemics: Development of the COVID-19 Risk Assessment Tool

Tools that can be used to collect behavioural data during pandemics are needed to inform policy and practice. The objective of this project was to develop the Your COVID-19 Risk tool in response to the global spread of COVID-19, aiming to promote health behaviour change. We developed an online resource based on key behavioural evidence-based risk factors related to contracting and spreading COVID-19. This tool allows for assessing risk and provides instant support to protect individuals from infection.

Impact of vaccine mandates and removals on COVID-19 vaccine uptake in Australia and international comparators: a study protocol

Vaccination against SARS-CoV-2 was a crucial public health measure during the COVID-19 pandemic. Among the multiple strategies developed to increase vaccine uptake, governments often employed vaccine mandates. However, little evidence exists globally about the impact of these mandates and their subsequent removal on vaccine uptake, including in Australia, France, Italy and the USA.

Show all
Infectious Diseases Epidemiology

Videos